Biotime receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lineage Cell Therapeutics Inc (LCTX)
Lineage Cell Therapeutics Inc stock price live, this page displays NYSE LCTX stock exchange data. View the LCTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lineage Cell Therapeutics Inc real time stock price chart below.
What Is the Lineage Cell Therapeutics Inc Stock Price Today?
The Lineage Cell Therapeutics Inc stock price today is 0.966.
What Is the Stock Symbol for Lineage Cell Therapeutics Inc?
The stock symbol for Lineage Cell Therapeutics Inc is ""LCTX.""
What Stock Exchange Does Lineage Cell Therapeutics Inc Trade On?
Lineage Cell Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Lineage Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Lineage Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LCTX quote. (ISIN: US53566P1093)
What Is the Lineage Cell Therapeutics Inc Stock Price Today?
The Lineage Cell Therapeutics Inc stock price today is 0.966.
What Is the Stock Symbol for Lineage Cell Therapeutics Inc?
The stock symbol for Lineage Cell Therapeutics Inc is ""LCTX.""
What Stock Exchange Does Lineage Cell Therapeutics Inc Trade On?
Lineage Cell Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Lineage Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Lineage Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LCTX quote. (ISIN: US53566P1093)
0.966
-0.024(-2.39%)
Real-time Data·
Fair Value
An estimate of a Lineage Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.966
1.020
52 wk Range
0.365
1.210
LCTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
LCTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Lineage Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9661.020
52 wk Range
0.3651.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LCTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Lineage Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
4.167
Upside
+331.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 8K Lineage Cell Therapeutics Inc For: 2 July
- Investing.com
- Biotime receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Lineage Cell Therapeutics Inc For: 2 July
- Investing.com
- Form 8K Lineage Cell Therapeutics Inc For: 23 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Lineage Cell Therapeutics Inc Company Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics Inc Earnings Call Summary for Q4/2024
- Q4 2024 revenue up $800,000 to $2.9M; full-year net loss improved to $18.6M from $21.5M in 2023
- Cash position strengthened to $47.8M, extending runway to Q1 2027; stock rose 1.69% in aftermarket trading
- Awaiting Roche/Genentech decision on OpRegen trial progression; focus on advancing cell therapy programs
- CEO confident in OpRegen potential for dry AMD; analysts maintain strong buy recommendation
- Revenue forecast indicates decrease in 2025; company expanding manufacturing capabilities and seeking additional funding
Last Updated: 10/03/2025, 22:38
Read Full TranscriptCompare LCTX to Peers and Sector
Metrics to compare | LCTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLCTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.8x | −5.1x | −0.5x | |
PEG Ratio | −0.33 | −0.08 | 0.00 | |
Price/Book | 2.8x | 3.5x | 2.6x | |
Price / LTM Sales | 23.4x | 10.0x | 3.3x | |
Upside (Analyst Target) | 203.0% | 489.8% | 43.5% | |
Fair Value Upside | Unlock | 2.1% | 6.9% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.167
(+331.33% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.02 / -0.03
Revenue / Forecast
1.50M / 2.01M
People Also Watch
FAQ
What Stock Exchange Does Lineage Cell Therapeutics Trade On?
Lineage Cell Therapeutics is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Lineage Cell Therapeutics?
The stock symbol for Lineage Cell Therapeutics is "LCTX."
What Is the Lineage Cell Therapeutics Market Cap?
As of today, Lineage Cell Therapeutics market cap is 220.59M.
What Is Lineage Cell Therapeutics's Earnings Per Share (TTM)?
The Lineage Cell Therapeutics EPS (TTM) is -0.08.
When Is the Next Lineage Cell Therapeutics Earnings Date?
Lineage Cell Therapeutics will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is LCTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Lineage Cell Therapeutics Stock Split?
Lineage Cell Therapeutics has split 1 times.
How Many Employees Does Lineage Cell Therapeutics Have?
Lineage Cell Therapeutics has 74 employees.
What is the current trading status of Lineage Cell Therapeutics (LCTX)?
As of 07 Aug 2025, Lineage Cell Therapeutics (LCTX) is trading at a price of 0.97, with a previous close of 0.99. The stock has fluctuated within a day range of 0.97 to 1.02, while its 52-week range spans from 0.37 to 1.21.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.